Phenelzine

MAOI interaction may manifest as serotonin syndrome or opioid toxicity including respiratory depression and coma. Use not recommended or within 14 days of stopping.

Nonselective MAO inhibitor use with carbidopa and levodopa is contraindicated. Discontinue at least two weeks prior to initiating therapy.

Concomitant use increases risk of serotonin syndrome. Contraindicated with MAOI or within 14 days of stopping MAOI.

Concomitant use increases risk of serotonin syndrome. Contraindicated with MAOIs intended to treat psychiatric disorders or within 14 days of stopping MAOI.

Concomitant use increases risk of serotonin syndrome. Contraindicated with MAOI intended to treat psychiatric disorders or within 7 days of stopping desvenlafaxine.

Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure.

MAOI that potentiates amphetamine effects; concomitant use can cause hypertensive crisis with potentially fatal outcomes including stroke, MI, aortic dissection.

MAOI concomitant use can cause hypertensive crisis with potentially fatal outcomes including stroke, myocardial infarction, and aortic dissection. Do not use concurrently or within 14 days after discontinuing.

Concomitant use increases risk of serotonin syndrome. Use of phenelzine with duloxetine or within 5 days of stopping duloxetine is contraindicated.

Nonselective MAO inhibitor use with VYALEV is contraindicated. Discontinue at least two weeks prior to initiating VYALEV.

Not recommended for patients taking MAOIs or within 14 days of stopping. May manifest as serotonin syndrome or opioid toxicity.

MAOI that increases risk of serotonin syndrome when used with levomilnacipran. Contraindicated use.

Meperidine is contraindicated in patients receiving MAOIs. Can cause unpredictable, severe, and occasionally fatal reactions including coma, respiratory depression, serotonin syndrome, convulsions, and hypertension.

Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, and other serious complications.

Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, aortic dissection, and renal failure.

Concomitant use increases risk of serotonin syndrome. Mirtazapine is contraindicated in patients taking MAOIs.

Do not use morphine in patients taking MAOIs or within 14 days of stopping treatment; may cause serotonin syndrome or opioid toxicity.

Use not recommended for patients taking MAOIs or within 14 days of stopping. Can cause serotonin syndrome or opioid toxicity including respiratory depression and coma.

Non-selective MAO inhibitor that inhibits catecholamine metabolism. Concomitant use may increase risk of arrhythmias, increased heart rate, and excessive blood pressure changes.

MAOI that increases risk of serotonin syndrome when combined with paroxetine. Paroxetine is contraindicated.

Concomitant use of SSRIs including paroxetine and MAOIs increases the risk of serotonin syndrome.

Concomitant use increases risk of serotonin syndrome.

Nonselective MAO inhibitor contraindicated with rizatriptan due to increased plasma concentrations and potential for serious adverse effects.

Concomitant use increases risk of serotonin syndrome. Sertraline is contraindicated in patients taking MAOIs.

Concomitant use of MAOI phenelzine with sertraline hydrochloride increases risk of serotonin syndrome.

MAOI interaction may cause serotonin syndrome or opioid toxicity. Do not use or within 14 days of stopping.

Concomitant use increases risk of serotonin syndrome. Trazodone is contraindicated in patients taking MAOIs.

Concomitant use with MAOIs increases risk of serotonin syndrome. Contraindicated with MAOI or within 14 days of stopping MAOI.

Inhibition of MAO prolongs and potentiates dopamine effects, potentially resulting in severe hypertension and cardiac arrhythmia.